Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Andolast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.51 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Andolast SCHEMBL4134029 | 0.98 | XDH (0.50) | XDHHPSEPTPN1GPR35MMP2 | |
| Andolast SCHEMBL1551317 | 0.98 | XDH (0.50) | XDHHPSEPTPN1GPR35MMP2 | |
| Andolast SCHEMBL1613902 | 0.97 | XDH (0.49) | XDHHPSEPTPN1GPR35MMP2 | |
| Andolast SCHEMBL1615202 | 0.97 | XDH (0.49) | XDHHPSEPTPN1GPR35MMP2 | |
| SCHEMBL3880312 | 0.91 | HDAC3 (0.56) | NPC1RAB9AMEN1LMNAKMT2A | |
| SCHEMBL28803661 | 0.87 | XDH (0.66) | XDHGPR35NPC1RAB9AMEN1 | |
| SCHEMBL28803588 | 0.86 | XDH (0.67) | XDHPOLBGAANPC1RAB9A | |
| SCHEMBL9341821 | 0.86 | MEN1 (0.50) | PTPN1POLBMEN1PKMKMT2A | |
| SCHEMBL9589707 | 0.86 | NPC1 (0.49) | PTPN1MMP2MMP9MMP8MMP13 | |
| SCHEMBL28803581 | 0.84 | XDH (0.68) | XDHNPC1RAB9AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962797-B2 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117746157-A | Lightweight image classification method and system based on neural network pruning | 湖南大学 | 2024-03-22 | — | — | CN | claimed |
| EP-1962797-B1 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2020-10-28 | — | — | EP | claimed |
| EP-3678690-A1 | METHODS FOR IMPROVING ADOPTIVE CELL THERAPY | Fred Hutchinson Cancer Research Center (US) | 2020-07-15 | — | — | EP | claimed |
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | claimed |
| CN-111065410-A | Methods for improving adoptive cell therapy | 弗雷德哈钦森癌症研究中心 | 2020-04-24 | — | — | CN | claimed |
| EP-2913062-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY AND METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY | JAPAN INNOVATIVE THERAPEUTICS INC (JP) | 2019-05-08 | — | — | EP | claimed |
| WO-2019051135-A1 | METHODS FOR IMPROVING ADOPTIVE CELL THERAPY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2019-03-14 | — | — | WO | claimed |
| EP-3354263-A1 | DRY POWDER FORMULATIONS | Jagotec AG (CH) | 2018-08-01 | — | — | EP | claimed |
| EP-3275435-A1 | DRY POWDER FORMULATIONS | Jagotec AG (CH) | 2018-01-31 | — | — | EP | claimed |
| CN-1150895-C | Dry Powder for inhalation | �ܸ��о��ɷݹ�˾ | 2004-05-26 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0896821-B1 | A novel pharmaceutical composition for inhalation containing CR 2039 (andolast) | ROTTA RESEARCH LAB (IT) | 2003-06-04 | — | — | EP | claimed |
| EP-1131059-B1 | DRY POWDER FOR INHALATION | JAGO RES AG (CH) | 2003-03-05 | — | — | EP | claimed |
| EP-1283036-A1 | Dry powder for inhalation | JAGO RESEARCH AG (CH) | 2003-02-12 | — | — | EP | claimed |
| CN-1326341-A | Dry powder for inhalation | JIG RES AG (CH) | 2001-12-12 | — | — | CN | claimed |
| EP-1131059-A1 | DRY POWDER FOR INHALATION | JAGO RESEARCH AG (CH) | 2001-09-12 | — | — | EP | claimed |
| WO-2000028979-A1 | DRY POWDER FOR INHALATION | JAGO RESEARCH AG (CH) | 2000-05-25 | — | — | WO | claimed |
| US-5976576-A | ACTIVE MATERIAL IS N-4-(1H-TETRAZOL-5-YL)PHENYL-4-(1H-TETRAZOL-5-YL)BENZAMIDE, DISODIUM SALT | ROTTA RESEARCH LABORATORIES S.P.A. (IT) | 1999-11-02 | — | — | US | claimed |
| EP-0896821-A1 | A novel pharmaceutical composition for inhalation containing CR 2039 (andolast) | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-02-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | SAE1, SDC4, SPECC1L | XDH 1541/4885HPSE 188/4885PTPN1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.